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Abstract
Background: 1E10 monoclonal antibody is a murine anti-idiotypic antibody that mimics N-glycolyl-GM3
gangliosides. This antibody has been tested as an anti-idiotypic cancer vaccine, adjuvated in Al(OH)3, in several
clinical trials for melanoma, breast, and lung cancer. During early clinical development this mAb was obtained
in vivo from mice ascites fluid. Currently, the production process of 1E10 is being transferred from the in vivo to a
bioreactor-based method.
Results: Here, we present a comprehensive molecular and immunological characterization of 1E10 produced by
the two different production processes in order to determine the impact of the manufacturing process in vaccine
performance. We observed differences in glycosylation pattern, charge heterogeneity and structural stability
between in vivo-produced 1E10 and bioreactor-obtained 1E10. Interestingly, these modifications had no significant
impact on the immune responses elicited in two different animal models.
Conclusions: Changes in 1E10 primary structure like glycosylation; asparagine deamidation and oxidation affected
1E10 structural stability but did not affect the immune response elicited in mice and chickens when compared to
1E10 produced in mice.
Background
Anti-idiotype vaccination represents an innovative
approach to target tumor-associated antigen-expressing
cells. This approach comes directly from Jerne’s idiotypic
network theory, which postulates that due to the huge
potentiality for diversity of the immunoglobulin variable
regions, the idiotype repertoire can mimic the universe of
self and foreign epitopes [1].
NeuGc-containing gangliosides are attractive targets
for cancer immunotherapy because these glycolipids are
non-self antigens in humans [2,3]. In contrast, they have
been detected in different human tumors by antibodies
and chemical analysis [4-6]. Recent experimental data
suggest that N-glycolyl-GM3 ganglioside (NeuGcGM3) is
relevant for tumor biology [7].
mAb-1E10 [8] is an IgG1 anti-idiotype (Ab2) mAb
obtained by immunizing Balb/c mice with mAb-P3 (Ab1)
[9] coupled to keyhole limpet hemocyanin (KLH) in the
presence of Freund’s adjuvant. This Ab2 inhibited the
binding of mAb-P3 to NeuGcGM3 ganglioside. mAb-
1E10 induced an idiotype-positive antigen-negative (Id
+Ag-) Ab3 response in syngeneic, allogeneic and xeno-
geneic models, where NeuGc-containing gangliosides are
normally expressed [8,10]. In contrast, in chicken, where
like in humans NeuGc-containing gangliosides are not
expressed in normal tissues, mAb-1E10 was capable of
inducing a specific Ab3 antibody response against these
gangliosides (Id+Ag+) [10]. Similar results have been
obtained in cancer patients immunized with Al(OH)3-pre-
cipitated mAb-1E10 [11-14]. The results of these clinical
trials evidenced that the vaccine was well-tolerated and
immunologically active. In addition, Al(OH)3-precipitated
mAb-1E10 immunization induced a pronounced anti-
metastatic effect in different murine tumor models [15,16].
For phase I and II clinical trials, mAb-1E10 was pro-
duced in mice ascites, a common practice in the 1990’s
for small scale antibody production.
We developed a new bioreactor-based method using
protein-free media for the production of mAb-1E10.
The mAb-1E10 produced from bioreactors (1E10-ST)
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has to be bioequivalent to ascites fluid-produced 1E10
(1E10-AF) in order to ensure the same effect in the
patients. In this case, this bioequivalence has to be
demonstrated by a set of physicochemical and biological
methods as required by regulatory authorities for char-
acterization of mAbs [17]. As mAb-1E10 is used as an
adjuvated vaccine additional characteristics should be
taken in to account.
Defining the molecular similarity of two mAbs can be
difficult due to their inherent heterogeneity. Apart from
the primary sequence, it has been established that glyco-
sylation can be critical for the biological function of
mAbs [18-21]. Product-related substances or impurities
such as deamidated, isomerized, and oxidized forms, or
protein aggregates [22-25] that may be introduced during
cloning and production processes can affect, both, the
mAbs’ tertiary structure and antigen-binding properties.
Therefore, a detailed characterization has special rele-
vance for idiotypic vaccines, where the correct spatial
atomic distribution in the Complementarity-Determining
Regions (CDRs) is critical for their biological activity.
Here, we present the detailed molecular and immuno-
logical characterization of mAb-1E10 obtained by two
different production methods in order to determine the
impact of the manufacturing process in vaccine
performance.
Results and Discussion
N-terminal pyroglutamic acid, Asn glycosylation and
three deamidation sites common for 1E10-AF and ST,
while oxidized methionine found only in 1E10-ST
Primary structure was determined by mass spectrometry
using both MALDI-TOF2 and ESI-QTOF for MS2 mea-
surements. The 1E10 amino acid sequence remained
unaltered during stirred tank fermentation or production
in ascites fluid. Post-translational modifications detected
were heavy chain N-terminal pyroglutamic acid, N-glyco-
sylation and the oxidation of methionine 396 (Figure 1),
as summarized in Table 1.
One common post-translational modification observed
in mAbs is a cyclized N-terminal glutamine [24,26-28]
when either the heavy and/or light chain sequences begin
Figure 1 Representative MALDI-TOF spectrum of 1E10 ST (upper panel) and 1E10 AF (lower panel). Sequences containing N-terminal
pyroglutamic acid and methionine 396 are shown at their corresponding m/z. The 16 Da mass shifts corresponding to methionine oxidation is
illustrated. Mass values corresponding to methionine oxidation were not detected in 1E10 LAM.
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with glutamine. This reaction involves the cyclization of
the N-terminal amine and the subsequent loss of NH3
(17 Da). The gene sequence of the heavy and light chains
of many mAbs codes for an N-terminal glutamine, but
upon sequencing the N-terminal amino acid is predomi-
nantly found as the cyclized pyro-glutamic acid form
[24,27,29]. Figure 2 shows the MS2 mass spectrum of the
N-terminal peptide from heavy chain which bears the
cyclized pyro-glutamic acid form of glutamine. Regardless
the source, ascites or stirred tank, all the heavy chain N-
terminal glutamines were found as pyro-glutamic acid,
exclusively.
Methionine oxidation is a chemical modification
known to change the stability and conformation of mAbs
through altering CH2 and CH3 domain structure [30,31].
Figure 1 shows the oxidation in residue Met396, which is
a conserved residue located at CH3 of IgG1 antibodies,
near to the region of interaction between CH2 and CH3
domains. This oxidation affects the overall charge and
stability of the antibody [32].
Deamidation has been shown to be one of the major
chemical degradation mechanisms in protein pharmaceu-
ticals during production and storage [33] Three sites of
Asn deamidation were found for mAb-1E10, two of these
were found in the constant region of the light chain and
the other one in the constant region of heavy chain, two
of these sites were also observed by Harris et al. [25]
studying MMA383 anti-idiotypic antibody.
Table 1 PTMs of mAb-1E10 detected by mass
spectrometry
Modifications 1E10 AF 1E10 ST
N-term glutamine to pyroglutamic acid + +
Glycosylation of Asn294 + +
Deamidation of Asn141 (heavy chain) + +
Deamidation of Asn157 (light chain) + +
Deamidation of Asn161 (light chain) + +
Oxidation of M396 + -
+ Modified.-Non Modified
Figure 2 Deconvoluted ms/ms spectrum of heavy chain N-terminal peptide containing pyroglutamic acid. y and b fragment ions
assigned are shown in the table and spectrum.
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Very low amounts of aggregates in 1E10-AF and ST, but
low molecular weight fragments present only in 1E10-AF
Aggregation analysis (Figure 3) revealed one major peak
corresponding to > 98% monomeric 1E10-ST eluting at a
retention volume of 7.6 mL. Additionally, a small amount
of dimers (< 2%) seemed to be present (vret = 6.9 mL).
1E10-AF showed two major peaks corresponding to > 91%
monomeric 1E10 eluting at a vret of 7.7 mL and 7.9% of
mAb fragments (vret = 8.6 ml) were determined. Dimers
seemed to be < 1% (vret = 6.9 ml).
Aggregates have been reported to cause immunogenicity
in a T cell-independent pathway [34]. As aggregates com-
prise a large number of individual protein molecules, there
is the potential for the surface to display a “repetitive”
Figure 3 Aggregation analysis of 1E10. HPSEC-TDA chromatograms of 1E10 ST (upper) and 1E10 AF (bottom). Refractive index (red), Log
Molecular Weight (black), Right Angle Light Scattering (green) and Log Radius (pale green) signals are shown. 1E10 ST revealed one major peak
corresponding to > 98% of monomers and a small amount of dimmers (< 2%). Two major peaks corresponding to > 91% monomeric 1E10
eluting and 7.9% of fragments with masses around 75 kDa were determined for 1E10 AF. Dimmers seemed to be < 1% for this mAb.
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array of epitopes that may be seen by the immune system
as resembling the external surfaces of pathogens, trigger-
ing the pattern recognition receptors (Toll-like receptors)
on APCs. This T-cell-independent pathway leads to an
IgM response. However, B cells activated by protein aggre-
gates could function as APCs to recruit T cell help and
thereby switch to an IgG response. Although B cells are
relatively poor APCs, their presentation potential is
enhanced following specific recognition of antigen, thus
contributing to initiation of T cell responses [35].
Among the various product-related impurities and
degradation products, aggregation is considered a strong
risk factor for immunogenicity. It is also the attribute
most difficult to control, because there are multiple factors
that can lead to the formation of aggregates in a product
[36].
Charge profile of 1E10-ST different from 1E10-AF even
after C-terminal lysine removal
Cation-exchange chromatography has been introduced to
measure charge heterogeneity, in particular caused by
lysine variants, more than 15 years ago [37] and now is
widely accepted in pharmaceutical analysis. We detected a
complex charge variety for both molecules consisting of
clusters of charged species (Figure 4). 1E10-AF remained
unaltered after enzymatic removal of C-terminal lysine
while in 1E10-ST the charged species changed dramati-
cally. The shape of the WCX chromatograms and the
changes observed after enzymatic treatment for both
1E10-AF and 1E10-ST suggested a complete processing of
C-terminal lysine in 1E10-AF, while the 1E10 obtained
from the stirred tank process was found to yield three
charged populations of C-terminal lysine processing
denoted in Figure 4 as 0 (mAb-1E10 with no C-terminal
lysine), 1 (mAb-1E10 with C-terminal lysine partially
removed), and 2 (intact mAb-1E10). Charged species pre-
sent on each cluster (a to e in Figure 4) can result from
posttranslational modifications like asparagine deamida-
tion, N-teminal pyroglutamic acid and methionine oxida-
tion determined by mass spectrometry. Harris et al [25]
reported similar findings as potential sources for the sig-
nificant charge heterogeneities in mAb-MMA383, an anti-
idiotypic murine IgG1 mAb. In that study C-terminal
lysine variants, proteolysis, and deamidation of light chain
Asn161 and heavy chain Asn141 were identified to be
responsible for mAb-MMA383 charge heterogeneity.
Same sugar structures attached to Fc of 1E10-AF and ST
but not their relative amount
Detailed N-glycosylation was investigated by N-glycan
mapping of fluorescence-labeled oligosaccharides
released from the mAbs. The 2-AB-labeled glycans,
Figure 4 WCX chromatograms of 1E10-ST (blue) and 1E10-AF (red). Gradient is represented in white (% A) and blue (% B), units are in the
right axis. Inverted chromatograms were recorded after carboxypeptidase b treatment. Charged species are denoted with letters; prefix numbers
indicate C-terminal lysine content for each peak. 1E10-ST gave rise to a continuous population of peaks due to the presence of terminal lysine
while 1E10-AF showed almost no C-terminal lysine.
Machado et al. BMC Biotechnology 2011, 11:112
http://www.biomedcentral.com/1472-6750/11/112
Page 5 of 13
released from mAbs by PNGase F, were separated using
hydrophilic interaction chromatography (HILIC) with
fluorescence detection for quantification. The N-glycans
identified were core-fucosylated biantennary-complex-
type oligosaccharides. Using GU values [38], the most
intense peaks were identified as agalactosylated core-
fucosylated biantennary (G0F) and monogalactosylated
core-fucosylated biantenary (G1F) structures, respec-
tively. Minor peaks with higher retention times were
determined to be core-fucosylated mono- and di-sialy-
lated biantennary structures, respectively.
Oligosaccharide structures were determined to be
similar for both mAb molecules. Six major glycans
(G0F, G1Fa, G1Fb, G2F, G2FS1 and G2FS2) were identi-
fied and quantified. Figure 5a shows a relative quantifi-
cation based on relative peak areas of 2AB-labeled
HPLC chromatograms. As expected, G0F, G1F and G2
were the most highly represented glycoforms in both
mAb-1E10, while sialylated glycoforms were less. Glyco-
sylation patterns of 1E10-ST and AF were determined
to be different in their ratios of glycan structures. How-
ever, they exhibited the same glycan structures attached
Figure 5 Comparison of HPLC separation and quantification of 2-AB-labeled glycans released from 1E10 ST and AF. a) Relative contents
of 2-AB-labeled glycans quantified by peak integration of HPLC-fluorescence signals.
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to Asn297 of heavy chain. Compared to 1E10-AF, bior-
eactor-produced mAb contained more G0 and displayed
a two-fold increase in sialylated forms. The glycan pat-
tern of 1E10-AF can be a result from enzymatic trim-
ming of oligosaccharides by glycosidases present in
ascites fluid. However, the 1E10-ST glycan pattern may
have resulted from differences in specific production
rates of hybridoma cells during fermentation. At high
production rates, mAb oligosaccharides result incom-
plete, while at low production rates, more complete
structures are produced.
IgG glycosylation plays a crucial role in antibody effec-
tor functions like cell-dependent cytotoxicity (CDC),
antibody-dependent cell cytotoxicity (ADCC), and FcgR
recognition. As the intended use of mAb-1E10 is to be
administered as a vaccine, adsorbed to alum, and injected
subcutaneously, it is very unlikely that Fc-mediated effec-
tor functions plays a critical role in the biological activity
of this mAb. However, conformation of IgG is affected by
glycosylation [32]. On the other hand, it is well known
that murine cells can attach highly immunogenic sugar
epitopes like aGal-Gal and N-glycolyl sialic acid [21]. As
the N-glycan structures of 1E10-AF and ST were identi-
cal, and so far none of these epitopes has been detected,
differences in immunogenicity and safety between 1E10-
AF and ST are not expected.
Reduced thermal stability of 1E10-ST as compared to
1E10-AF
Thermally induced structural transitions in the secondary
structure monitored by infrared spectroscopy have been
previously described [39-42] to analyze the unfolding
behavior of proteins and to determine a melting tempera-
ture (TmFTIR). As structural transition to intermolecular
b-sheets occur regardless of the initial secondary structure
composition of the native protein, these bands can be used
to monitor protein aggregation in aqueous solution and
solid state [33]. The melting point can be determined by
plotting the ratio of the intensities of characteristic amide
I bands vs. temperature [43]. 1E10-AF and 1E10-ST
displayed a different behavior under temperature stress
(Figure 6). While 1E10-AF remained in solution, 1E10-ST
started melting at approximately 73°C. One explanation
for the lower thermal stability of 1E10-ST might be the
oxidized Met396 in 1E10-ST, which was not detectable in
1E10-AF. This residue is located on CH3 domain, near to
the interaction site of CH2 and CH3, therefore, it may be
hypothesized that oxidation of this residue can affect the
three dimensional structures of CH3 and CH2 and here-
with the overall stability of the antibody. In summary, the
thermal stability for mAb-1E10 obtained in stirred tank
fermentation was lower than mAb-1E10 obtained in
ascites fluid, supported by several factors including
methionine oxidation, differences in glycan patterns,
charge state heterogeneities, and protein conformation.
Similar Ab3 antibody responses elicited by 1E10-AF and
ST vaccination in chicken
We compared the specificity of the antibodies generated
in chicken by immunization with 1E10-AF and ST. Anti-
body responses were tested in the sera obtained from the
animals after the immunization. All chicken developed a
strong humoral response against the whole mAb-1E10
molecules. The titers of Ab3 responses were higher than
1/400,000, as measured by ELISA (Figure 7). The reactiv-
ity of animal sera with the murine isotype-matched mAb
was also tested, and a higher binding to the immunizing
mAb-1E10 was observed in the chicken sera indepen-
dently of the source of anti-idiotype mAb (Figure 7) (p <
0:001, one way analysis of variance and Bonferroni multi-
ple comparisons tests). This result demonstrated the
immunodominance of the idiotype of both mAb-1E10
products in the antibody response induced in immunized
chicken. Moreover, there was no difference in the serolo-
gical antibody titers obtained when the animals were
immunized with 1E10-AF or 1E10-ST (p > 0.05) (Figure
7), evidencing the same immunogenicity for these two
mAb-1E10 molecules. Thus, the structural changes
observed did neither affect overall immunogenicity nor
the idiotypic immunodominance reported for this mAb
[10].
Co-administration of 1E10-AF/Alum or 1E10 ST/Alum with
low-dose Cyclophosphamide induced anti-tumor effects
in a mammary carcinoma model
As shown in Figure 8, no antitumor effect was observed
when low-dose Cyclophosphamide or 1E10-ST/Alum was
administered alone at the evaluated dose. Interestingly,
when 1E10-AF/Alum or 1E10-ST/Alum was co-adminis-
tered with low-dose Cyclophosphamide F3II mammary
carcinoma growth was reduced significantly. No statistical
differences in tumor growth between these groups of mice
were determined and the observed anti-tumor responses
were comparable with the effect upon co-administration
of the standard high-dose chemotherapy for breast cancer
based on 60 mg/m2 of Doxorubicin and 600 mg/m2 of
Cyclophosphamide.
In vivo experiments resulted in similar immunogeni-
city, idiotypic dominance, and antitumor effects of 1E10-
AF and 1E10-ST. Thus, the observed posttranslational
modifications did most likely not affect the Fab structure,
as the biological activity of 1E10 vaccine was not altered.
Moreover, deamidation of asparagine and methionine
oxidation were restricted to Fc regions in 1E10 mAb, far
away from CDRs. Therefore, it remains unlikely that
these amino acid modifications might affect the spatial
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conformation of the respective CDRs enabling structural
mimicry as postulated for anti-idiotypic mAbs.
Conclusions
Effector functions of classic therapeutic monoclonal
antibodies can be divided in Fab-dependent functions
and Fc-dependent functions. The Fab region contains
variable regions of light and heavy chains which are
responsible for antigen recognition, while the Fc region
mediates effector functions like CDC, ADCC and FcgR
recognition. Therefore, any change in their physico-
chemical profile could eventually affect the efficacy of
mAbs.
It is well known that physicochemical properties of
recombinant proteins can be heavily affected during
changes in the production process. Thus, it is manda-
tory to carefully investigate the similarities and differ-
ences of therapeutic mAbs when the production process
has been changed. Comparability must be demonstrated
by an array of physicochemical and biological methods
as required by the regulatory authorities.
Regulatory aspects regarding physicochemical charac-
teristics of idiotypic monoclonal antibodies used for
idiotypic vaccination bear some differences from classic
therapeutic mAbs. For idiotypic mAbs, Fc-related func-
tions are not critical for the intended biological effect as
they are administered adsorbed to alum and via intra-
dermis. Antigen mimicry is restricted to variable region
CDRs which are located in Fab.
Here, we demonstrate that change of 1E10 production
from ascites to bioreactor generates a molecule with dif-
ferent physicochemical properties. Changes were
observed in the degree of asparagine deamidation, C-
terminal lysine processing, methionine oxidation, and
glycosylation pattern. All these modifications had an
impact on the charge profile and conformation of the
1E10 molecule, as revealed by an altered thermal stabi-
lity of 1E10-ST. However, these changes did not affect
Figure 6 Thermal transition curves of the 1E10-AF (dotted line) and 1E10-ST (solid line). Curves were obtained by plotting the ratio of the
intensities of the increasing to the decreasing amide I band vs. temperature. 1E10-ST showed different thermal stability in respect to 1E10-AF.
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Figure 7 Specificity of Ab3 antibodies to 1E10-AF and 1E10-ST in sera from immunized chicken determined by ELISA. Chicken sera at
different dilutions were bound to microtiter plates coated with 1E10-AF, 1E10-ST or isotype-matched control ior C5 mAb (10 μg/mL) and the
reaction was developed with alkaline phosphatase-conjugated rabbit anti-chicken IgY. Sera were obtained seven days after animals received the
third dose of each 1E10 mAb preparation. The data represent mean ± SD of maximal titers in chicken sera of each group.(p < 0:001, one way
analysis of variance and Bonferroni multiple comparisons test). Similar letters means no difference (p > 0.05). Baseline serological antibodies were
undetectable (< 100 titer).
Figure 8 Antitumor effects of 1E10-AF/Alum and 1E10-ST/Alum co-administrated with low-dose Cyclophosphamide in a mammary
carcinoma model. F3II tumor-bearing mice were immunized subcutaneously with 100 μg of 1E10-ST/Alum alone (open triangle); 1E10-AF/Alum
(open circle) or 1E10-ST/Alum (open square) combined with 150 mg/m2 of Cyclophosphamide i.v. 7 days after the tumor inoculation. Both
combinations reduced significantly the F3II mammary carcinoma growth. This response was comparable with the administration of high-dose
chemotherapy based on 60 mg/m2 of Doxorubicin and 600 mg/m2 of Cyclophosphamide (full triangle). * Significant differences (P < 0.05) using
Kruskal-Wallis and Dunn’s multiple comparison tests.
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its biological activity. The idiotypic dominance was not
affected, which represents the intended effect for an
idiotypic vaccine. Thus, the transfer in the production
process of 1E10 idiotypic mAb from ascites to bioreac-
tor improved product safety without affecting its bio-
logical activity. Furthermore, our study demonstrated a
number of physicochemical properties that do not affect
the biological activity of 1E10 idiotypic vaccine.
Methods
1E10-AF
Hybridoma cell line was cultured in DMEM/F-12 med-
ium supplemented with 5% of fetal calf serum (Invitro-
gen, USA), 5 mM of glutamine (Invitrogen, USA), 2.546
g/L of HEPES (Sigma, USA), 2.18 g/L of sodium bicar-
bonate (Sigma, USA) and 1 mL/L of 2-mercaptoethanol
(Sigma, USA). Mouse ascites fluid from BALB/c mice
was sterilized by depth filtration and 1E10 mAb was
purified using the following chromatographic sequence:
ion exchange by DEAE Sepharose, affinity chromatogra-
phy using Protein A Sepharose, and Sepharose G-25 gel
filtration chromatography (all from GE Heathcare,
USA).
1E10-ST
Supernatant of 1E10-ST was obtained from the stirred
tank bioreactors hybridoma cell culture using a proprie-
tary protein free medium in perfusion mode. Clarified
1E10 supernatant was purified by protein A affinity
chromatography using ProSep vA ultra matrix (Milli-
pore, USA, followed by cation exchange chromatography
(SP Sepharose FF, GE Healthcare, USA) and Sepharose
G-25 size exclusion chromatography (GE Healthcare,
USA).
Aluminum hydroxide-precipitated 1E10-AF and 1E10-ST
mAb formulations
Purified mAb-1E10 molecules were aseptically mixed at a
final concentration of 1 mg/ml with 5 mg/ml of aluminum
hydroxide as adjuvant (Superfos Biosector, Frederikssund,
Denmark). The mixture was gently stirred for 3 h at room
temperature. The aluminum hydroxide-precipitated mAb
was stored in aliquots at 4°C until use.
Amino acid sequence and posttranslational modifications
(PTMs) analysis
Lyophilized mAbs (50 μg) obtained from each process
were dissolved in 50 μL of 25 mM of Tris-HCl buffer, pH
8.5 with 8 M Urea. After addition of DTT to a final con-
centration of 50 mM, the mixture was flushed with N2
and incubated for 3 h at 37°C. Following this step the sam-
ple was cooled to room temperature, acrylamide was
added to a final concentration of 100 mM and the mixture
incubated for 20 min in the dark at room temperature.
The samples were diluted 8 times to a final concentration
of 1 M Urea. After addition of 1 μg trypsin, the mixture
was incubated at 37°C for 18 h. The reaction was stopped
by addition of 2% (v/v) TFA in water. The peptide mixture
was analyzed directly by MALDI-MS and ESI-MS.
Analyses of peptides by MALDI-TOF2 MS were per-
formed on an Axima Performance mass spectrometer
(Shimadzu Biotech, Japan) equipped with a 337 nitrogen
laser and a collision-induced dissociation (CID) chamber
with helium gas. Analyses were carried out in reflector
mode (Mr < 5000) with delayed extraction. The instru-
ment was calibrated externally using ProteoMass Peptide
Calibration kit (Sigma), low mass gate value of 700 was
selected. Data analyses were performed using Shimadzu
Biotech Launchpad software (Shimadzu Biotech, Japan)
Digested peptides were purified using CleanUp Pippet
Tips C18 (Agilent, USA) as recommended by the manu-
facturer. Sample was deposited on the MALDI plate by
the dried-droplet sample preparation method [44] using
a-cyano-4-hydroxycinnamic acid (CHCA), 10 μg uL-1,
in TFA-water-acetonitrile (0.1:30:70, v/v).
ESI-MS and MS2 were performed in the positive ion
mode on a Micromass Q-TOF II mass spectrometer
(Manchester, UK) equipped with a Z-spray sample intro-
duction system. Acquisition and analysis of the data was
performed using MassLynx software v 4.0 (Micromass,
Manchester, UK). For calibration, a sodium and cesium
iodide mixture solution was used.
Aggregation analysis
High performance-size exclusion chromatography
(HPSEC) of 100 μl sample was performed as standard
using a 7.8 × 300 mm TSKgel G2000SWXL column pro-
tected by a 6 × 40 mm guard column (Tosoh Bioscience,
Stuttgart, Germany) on a HP1100 analytical chromatogra-
phy system (Hewlett-Packard, San Jose, CA, USA) at 0.5
ml/min in 100 mM sodium phosphate pH 6.6, 150 mM
NaCl, 0.05% NaN3. Using a combination of the built-in
UV detector measuring at 280 nm and a sequential refrac-
tive index (RI), intrinsic viscosity (IV), and right-angle
light scattering detection (TDA 302, Viscotek Corp.,
Houston, TX, USA) the MW and hydrodynamic radius of
eluting peaks were determined. Detector calibration was
performed using bovine serum albumin from Sigma
(A7638) weighed out at 1.0 mg/ml.
Thermal stability of mAb-1E10 by FTIR
Infrared spectra were recorded using a Tensor 27 spectro-
meter (Bruker Optics, Ettlingen, Germany). Protein sam-
ples were prepared in a BioATR cell connected to a
thermostat. For each spectrum, a 120 scan interferogram
was collected in single beam mode at 4 cm-1 resolution.
Reference spectra were recorded under identical conditions
with only the reference buffer in the cell. To determine the
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melting temperature (TmFTIR), temperature-dependent
spectra were acquired every 5°C in a ranging from 25 to
90°C. Recorded infrared spectra were analyzed by the Pro-
tein Dynamics software for Opus 4.2 (Bruker Optics) and
displayed as vector-normalized second-derivative amide I
spectra. Melting temperature was calculated by plotting the
1639 cm-1 to 1625 cm-1 signal ratio vs. temperature.
Analysis of charge heterogeneity
1E10-ST and 1E10-AF (approximately 100 μg each) were
diluted five-fold with buffer A (10 mM sodium acetate pH
5) loaded onto a ProPac10 WCX column (Dionex, Hous-
ton, USA) and eluted with buffer B (10 mM sodium acet-
ate, 1 M NaCl pH 5). The gradient was performed in two
steps, from 8 to 13% B in 5 min and 13 to 20% B in 20
min. Protein elution was monitored by absorbance at 280
nm.
The mAb solutions (1.5 mg/ml in 15 mM sodium
phosphate pH 7) were treated with carboxypeptidase B
(Boehringer, Germany) at an enzyme-to-substrate ratio
of 1:5000 (w/w) at 25°C. Reaction was stopped by add-
ing 1 μl of acetic acid. Digested samples were analyzed
by WCX HPLC as described above.
N-Glycosylation analysis
N-glycans were released by digestion with peptide-N4-(N-
acetyl-b-d-glucosaminyl) asparagine amidase F (PNGase F,
BioLabs, Beverly, MA, USA), using the method described
by the manufacturer. Briefly, mAbs-1E10 were denatured
at 100°C for 10 min in 0.1% SDS, 5% b-mercaptoethanol.
Nonidet P-40 (NP-40) was added to a final concentration
of 1% before enzyme addition. The digestion was carried
out at a ratio of 5 U of PNGase F per milligram of glyco-
protein at 37°C for 2 h. The protein was precipitated by
adding three volumes of cold ethanol and the mixture was
kept at -20°C for 30 min. The oligosaccharides were con-
centrated under vacuum and subjected to 2-aminobenza-
mide (2AB) labeling.
Oligosaccharides were fluorescently labeled with 2AB by
reductive amination [45]. Briefly, oligosaccharides were
dissolved in 5 μL DMSO-acetic acid (7:3) containing 2AB
(0.35 M) and 1 M NaCNBH3 and incubated at 65°C for 2
h. Excess of fluorophore was removed by 2 h vertical chro-
matography on Whatman 3 MM paper using acetonitrile.
The paper bearing the oligosaccharide signal (application
point) was cut. The oligosaccharides were eluted from the
paper by adding double-distilled water (2 × 500 μL). The
eluate was filtrated in a syringe through a 0.45 μm PTFE
filter (Millex-LCR, Millipore) and then concentrated
under vacuum.
Normal-phase HPLC (NP-HPLC) of the labeled por-
tion was performed using a TSK-Gel Amide-80 4.6 × 250
mm column (Tosoh BioSep, Japan) on a separation mod-
ule (Merck-Hitachi, Japan) equipped with a fluorescence
detector. Labeled N-glycans were separated by a linear
gradient of 20-58% of 50 mM ammonium formiate pH
4.4 against acetonitrile over 152 min at a flow rate of 0.4
mL/min. Samples were injected in 80% acetonitrile. The
fluorescence detection was carried out using an excita-
tion wavelength of 330 nm and an emission wavelength
of 420 nm [46]. The elution positions of the N-glycans
were determined in glucose units (GU) by comparison
with a standard dextran hydrolysate 2AB labeled (dextran
ladder) [47].
Animals
Female BALB/c/cenp mice (ten weeks old) and Leghorn
chicken (10 weeks old) were purchased from the Center
for Laboratory Animal Breeding (CENPALAB, Havana,
Cuba). Animals were housed under conventional condi-
tions with free access to water and food and maintained
in accordance with the guidelines stipulated by the Ani-
mal Subject Committee Review Board of CENPALAB.
Animal studies were performed with approval from
CENPALAB’s and CIM’s Institutional Animal Care and
Use Committees.
Antitumor experiments
The sarcomatoid mammary carcinoma cell line F3II is a
highly invasive and metastatic variant established from a
clone of a spontaneous BALB/c mouse mammary tumor.
F3II cells grow as spindle-cell carcinoma tumors with a
high local invasiveness and a 90-100% incidence of lung
metastases [48]. F3II cells were maintained in minimal
essential medium (MEM 41500, Gibco, BRL) supplemented
with 10% fetal bovine serum, 2 mM glutamine, 80 mg/ml
Gentamycin, and 20 mg/ml tetracycline in monolayer
culture.
All mice were injected subcutaneously with 2 × 105 F3II
cells in the right flank. Seven days after tumor inoculation,
the animals were separated in different groups and
injected as follows: subcutaneously with normal saline;
subcutaneously with 100 μg of 1E10-ST/Alum; intrave-
nously with 150 mg/m2 of Cyclophosphamide (Cy-150);
intravenously with 150 mg/m2 of Cyclophosphamide and
subcutaneously with 100 μg of 1E10-AF/Alum; intrave-
nously with 150 mg/m2 of Cyclophosphamide and subcu-
taneously with 100 μg of 1E10-ST/Alum or intravenously
with 60 mg/m2 of Doxorubicin (Dox) and 600 mg/m2 of
Cyclophosphamide (Cy-600). The time of appearance of
local tumors was monitored by palpation and further con-
firmed by histopathology. In all cases, tumors were diag-
nosed as spindle-cell carcinomas. Tumor size was
measured with a caliper twice a week.
Induction of anti-anti-idiotype antibody (Ab3) response
Chicken were immunized subcutaneously with 100 μg of
1E10 vaccine in the days 0, 7 and 21. Blood extractions
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were done before and one week after the last immuniza-
tion (day 28).
The presence of anti-1E10 antibodies in chicken sera
was determined in a solid-phase ELISA Polystyrene Maxi-
sorp microtiter plates (Nunc, Roskilde, Denmark) were
coated with 50 μl of a solution of 10 μg/ml of mAb-1E10
in carbonate buffer pH 9.6 and incubated overnight at 4°C.
After washing with PBS containing 0.05% Tween 20, the
plates were blocked for 1 h at room temperature with PBS
containing 1% BSA. Then, diluted serum samples were
added to each well and the plates were incubated for 2 h
at 37°C. Chicken antibodies were detected with an AP-
conjugated rabbit anti-chicken IgY (Sigma). The plates
were washed four times and the reaction was developed
with a substrate solution consisting of 1 mg/ml p-nitro-
phenylphosphate (Sigma) in diethanolamine buffer, pH
9.8. Absorbance was measured at 405 nm in an ELISA
reader (Tekan, Salzburg, Austria).
The highest serum dilution giving OD values ≥0.2 and
being at least three times the value corresponding to the
preimmune serum at the same dilution was considered
as titer. Assays were performed in triplicate for each sam-
ple and the coefficient of variation (CV) was less than
15%. The ODs of the blanks were less than 0.1.
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